Gut bacteria cause memory loss in mice, but restoring gut-brain signals reverses it

Targeting gut bacteria, their metabolites, or gut-to-brain signaling could offer new strategies to prevent or treat age-related memory decline. 

VOWST eyes Europe as IdB Holding and Nestlé Health Science bet on microbiome therapeutics

The agreement covers the development and future commercialization in Europe of VOWST®, the first oral LBP approved in the United States to prevent recurrent Clostridioides difficile infection.

Biotics in infant formula: promising evidence, but stronger clinical studies are needed

To better define the role of biotics in infant formula, future studies should be specifically designed to assess infection prevention, with adequate sample sizes, harmonised formulations and long-term follow-up.

Medicine is organised by body parts. Biology never got the memo.

The question for the next decade is whether healthcare institutions can reorganise around a biology they did not anticipate—one that is relational, systemic, and indifferent to the departmental boundaries medicine…

A model for electron transfer in the gut microbiome

B. luti plays a crucial role in maintaining gut homeostasis, microbial electron transfer and gut health by producing beneficial metabolites and regulating formate and hydrogen levels.

Gut bacterium triggers immune cells to kill colorectal tumors

Modulating the gut microbiota could be a new strategy to harness immune cells for treating colorectal cancer.

New study shows Bimuno® GOS supports gut barrier integrity and immune health in athletes

New study adds further strength to the evidence behind Bimuno GOS’ ‘performance powered by gut health’ approach.

Gut bacteria may shape colon cell identity and protect against disease

Gut microbes, through metabolites such as niacin, shape the regional identity and protective functions of colon cells.

High sugar may promote severe fatty liver disease through gut bacteria

The findings suggest that L. salivarius can be a microbiota-based therapy for preventing severe fatty liver disease progression.

IBS Days: bridging science and clinical practice in irritable bowel syndrome

Giovanni Barbara (University of Bologna), Congress Chair, reflects on the key takeaways from the congress and shares his closing remarks.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.